Allicin Reverses Diabetes-Induced Dysfunction of Human Coronary
Artery Endothelial Cells
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RESULTS

ABSTRACT
Allicin reverses diabetes-induced depression of NO Production in HCAEC
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Cardiovascular disease (CVD) is the leading cause of death in the United States, and is the
major source of morbidity and mortality associated with diabetes mellitus. Because the
incidence of diabetes continues to increase, reducing the risk of CVD in diabetes will
continue to be a major focus of cardiovascular research. An early manifestation of diabetesinduced CVD is dysfunction of the vascular endothelium, as indicated by depressed
production of NO. Our findings now demonstrate depressed activity of endothelial nitric
oxide synthase (eNOS) in diabetes, and suggest that treating human coronary artery
endothelial cells with allicin, the major bioactive organosulfur component in garlic extract,
can restore NO production in these cells. Coronary artery endothelial cells (Lonza) were
obtained from control (HCAEC) or diabetic (DHCAEC) donors, and NO production was
measured by fluorescence microscopy via 4,5-diaminofluorescein diacetate. On average,
NO production was depressed by 12.9% in DHCAEC compared to controls. Treating these
cells for 20 minutes with 4μM allicin restored NO production by 32.9%. Further, immunoblot
studies revealed that diabetes decreased expression of eNOS protein by 20.3%; however,
allicin was able to reverse this effect of diabetes. On average, eNOS expression was
increased by 26% by overnight exposure to 5μM allicin. Taken together, these data indicate
that allicin improves endothelium-dependent NO production in diabetes by enhancing the
expression and/or activity of eNOS in human coronary artery endothelial cells. These
studies further suggest that this improved endothelial function likely contributes to the
established health benefits of garlic consumption (e.g., lowering blood pressure), and also
suggests a natural means of reducing the devastating consequences of diabetes on CVD.
Future experiments are needed to identify the mechanism of allicin action on eNOS and in
vascular endothelial cells.
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Diabetes mellitus is a consistent rising public health burden in the 21st century, and remains
a major risk factor for the development of CVD. Currently, diabetes affects over 125 million
people in the western world, and estimates of its prevalence are expected to surpass 300
million by 2025 due to a combination of poor diet and lifestyle. Natural garlic (Allium
sativum) supplementation has been utilized as a remedy for thousands of years in treating
various chronic diseases. Allicin (2-propene-1-sulfonothioic acid S-2 propenyl ester, diallyl
thiosulfinate) is the primary active component in garlic, and current literature supports its
therapeutic effects on lowering blood pressure, decreasing blood glucose levels, reducing
atherosclerotic plaque formation, and modulating inflammation. This organosulfur
compound rapidly crosses the cellular membrane and reacts with sulfhydryl groups on
cellular proteins or with glutathione. It has been demonstrated that allicin increases
intracellular levels of glutathione and phase II detoxifying enzymes that include glutamatecysteine ligase and heme oxygenase-I in vascular endothelial cells. We tested the
hypothesis that allicin could reverse diabetes-induced inhibition of NO production in human
coronary artery endothelial cells, possibly by decreasing oxidative stress to lower CVD risk.

+ Allicin + L-NAME

Figure 1. Effect of allicin on NO production and inhibition by L-NAME in DHCAEC-I cells. A. Representative images of NO
production by DHCAEC-I cells untreated (left panel) allicin-treated (middle panel), and treated with allicin and L-NAME (right
panel). B. Baseline DAF fluorescence was 8433 + 6276, n=36 cells. Allicin increased mean fluorescence intensity by 292.39% from
baseline (33090 + 7705 n=18 cells). L-NAME, an inhibitor of eNOS activity, attenuated mean flourescence intensity to 5057+ 5043,
n=47 cells. This is a 554.34% decrease from allicin treatment. Data are expressed as mean + SEM. Student’s t test was performed.
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Our findings demonstrate that allicin:
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Figure 2. L-NAME, an inhibitor of eNOS, attenuated NO production and sodium nitroprusside (SNP) increased NO production in
HCAEC. Baseline DAF fluorescence was 7.062 + 0.3603 NFU, n=119 cells. L-NAME decreased intensity by 98.3% from baseline,
(mean 0.1206 + 0.111 NFU, n=41 cells.)_Subsequent treatment with SNP, an exogenous NO donor, significantly increased DAF
intensity to 16.43 + 2.543 NFU, n=41 cells. This is a 13,524% increase from L-NAME and a 132.7% increase from baseline. Data
analyzed using Student’s t test.

4.) modified the eNOS immunocomplex in DHCAEC-I cells
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Cell Culture: Human coronary artery endothelial cells (HCAEC) from healthy, Type-I, and
Type II diabetic cell lines(DHCAEC-I; DHCAEC-II) were grown in EBM-2 basal media
supplemented with EGM-2 MV (Lonza). Passage 4 cells were thawed and used for
treatment. Cells were changed to phenol-free media 24 hours prior to imaging.
Allicin Treatment: Cells were incubated in 10μM 4,5-Diaminofluorescein diacetate (DAF2DA) for 15 minutes at 37°C. Cells were then washed with KREBS solution and incubated
for 20 minutes at 37°C. Afterwards, cells were incubated with L-NAME and images were
obtained with EVOS microscope at 10X, 20X, 40X and analyzed using ImageJ software.
Immunoblotting: Cell lysates (20μg of protein) were analyzed by 8% Tris Glycine SDS
polyacrylamide gel electrophoresis and transferred to PVDF membrane. The membranes
were blocked with 5% milk + TBST 0.1% for 1 hour and then probed overnight with a antieNOS antibody (1:10000). Membranes were then incubated with species-specific HRPconjugated secondary antibody (1:5000) followed by detection with ECL substrate.
METHODby densitometry analysis of scanned films using
Quantitation of proteins was determined
ImageJ software.
Mass Spectrometry: Proteins were extracted from cell lines and equal amounts were
immunoprecipitated with anti-eNOS antibody or control goat IgG. The immune complexes
were immobilized on the protein A/G ultralink resin. Trypsin digestion and MS analysis were
performed at the proteomics and metabolomics core facility at the Georgia Cancer Center.
Scaffold (version Scaffold_4.8.9, Proteome Software, Inc.) was used to validate LC-MS and
LC-MS/MS-based peptides and protein identification. Peptide identifications were accepted if
they could be established at >95.0% probability as specified by the Peptide Prophet
algorithm.

Figure 4. Analysis of eNOS immunocomplex induced by allicin treatment in DHCAEC-I cells by mass spectrometry (MS). To identify proteins, immunocomplexes were
isolated from allicin-treated and non-treated DHCAEC-I cells using an anti-eNOS antibody and control IgG. LTQ Orbitrap MS was then used to analyze tryptic peptides
generated following an immunoprecipitation. A. Highest ranking of proteins associated with eNOS complex induced by allicin. 156 indicated as DHCAEC-I cells. B.
Quantitative scatterplot demonstrated proteins involved in the eNOS immunocomplex of non-treated versus allicin treated DHCAEC-I cells. C. Venn diagram
representing the amount of proteins associated with the eNOS immunocomplex in each experimental group. 883 proteins are represented in the allicin specific
immunocomplex of DHCAEC-I cells. D. Representative protein (glutathione synthetase, accession A0A2R8Y6Y6_HUMAN) specific for allicin induced eNOS
immunocomplex.
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Our data provide supporting evidence for the potential use of allicin as a preventative measure against CVD. We
propose that allicin may aid in treatment of endothelial dysfunction associated with type-I diabetes or other
conditions of high oxidative stress. Future research is needed to analyze the role of specific proteins involved in the
eNOS immunocomplex induced by allicin.
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Figure 3. Allicin increased eNOS expression. A. Representative immunoblot analysis for eNOS in HCAEC, DHCAEC-I, and DHCAEC-II
cell lines. β-actin was used as loading control. B. Quantification of eNOS expression in non-treated and allicin treated cell lines of
HCAEC (n=3), DHCAEC-I (n=3), and DHCAEC (n=3). The data are expressed as mean + SEM. Data analyzed using Student’s t test.
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